
Ocular Therapeutix (OCUL) Stock Forecast & Price Target
Ocular Therapeutix (OCUL) Analyst Ratings
Bulls say
Ocular Therapeutix Inc. has a promising outlook due to its consistent annual revenue growth from Dextenza since its launch in July 2019, indicating strong market acceptance and demand for its products. The company's proprietary hydrogel platform technology shows significant improvements in eye conditions, with positive clinical trial results for Axpaxli expected to further boost its market potential. Additionally, the anti-VEGF treatment class is projected to grow at a CAGR of 8%-10% through 2028, positioning Ocular to benefit from this expanding market as it captures established market share forecasts.
Bears say
Ocular Therapeutix has experienced a significant decline in sales, reporting a 68% year-over-year decrease attributed to market share erosion from competitors such as Eylea and Vabysmo, alongside pressure from newly introduced biosimilars. While Dextenza's revenue for the fourth quarter of 2024 met the company’s guidance at $17 million, it fell slightly short of consensus estimates, indicating challenges in maintaining growth within its portfolio. Additionally, the delay of pivotal data for the promising candidate Axpaxli to early 2026 raises concerns about the company's future prospects, escalating the risk associated with its ongoing clinical trials and overall valuation.
This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.
Ocular Therapeutix (OCUL) Analyst Forecast & Price Prediction
Start investing in Ocular Therapeutix (OCUL)
Order type
Buy in
Order amount
Est. shares
0 shares